Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eli Lilly

780.67
+1.390.18%
Post-market: 780.00-0.6700-0.09%16:58 EDT
Volume:1.45M
Turnover:1.13B
Market Cap:739.87B
PE:66.67
High:783.55
Open:780.46
Low:773.00
Close:779.28
Loading ...

Eli Lilly and Co - Declares Q3 2025 Dividend of $1.50 per Share

THOMSON REUTERS
·
23 Jun

Press Release: Lilly declares third-quarter 2025 dividend

Dow Jones
·
23 Jun

Eli Lilly Stock (LLY) Pops as Weight-Loss Drug Data from Rival Novo Nordisk Disappoints

TIPRANKS
·
23 Jun

Eli Lilly Shares up 2.5%

THOMSON REUTERS
·
23 Jun

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Legend Biotech (LEGN), Eli Lilly & Co (LLY) and Exelixis (EXEL)

TIPRANKS
·
23 Jun

PRESS DIGEST-British Business - June 23

Reuters
·
23 Jun

Eli Lilly announces orforglipron met primary endpoint in ACHIEVE-1 study

TIPRANKS
·
23 Jun

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated a1c Reduction and a Safety Profile Consistent With Daily Insulin in Multiple Phase 3 Trials

THOMSON REUTERS
·
23 Jun

Lilly Expects Orforglipron Obesity Results In Third Quarter

Reuters
·
22 Jun

BRIEF-Lilly's Oral Glp-1, Orforglipron, Showed Compelling Efficacy And A Safety Profile Consistent With Injectable Glp-1 Medicines, In Complete Phase 3 Results Published In The New England Journal Of Medicine

Reuters
·
21 Jun

Lilly's Oral Glp-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent With Injectable Glp-1 Medicines, in Complete Phase 3 Results Published in the New England Journal of Medicine

THOMSON REUTERS
·
21 Jun

Eli Lilly and Co - Remains on Track to Submit Orforglipron for Weight Management by End of Year

THOMSON REUTERS
·
21 Jun

Eli Lilly and Co - Orforglipron Lowers a1c by 1.3% to 1.6% in Phase 3 Trial

THOMSON REUTERS
·
21 Jun

Guggenheim Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

TIPRANKS
·
21 Jun

Eli Lilly & Co. Stock Falls 2.8%, Underperforms Competitors

Dow Jones
·
21 Jun

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Reuters
·
21 Jun

Eli Lilly Price Target Maintained With a $936.00/Share by Guggenheim

Dow Jones
·
20 Jun

Market Chatter: Lilly to Appeal Against UK Regulator's Recommendation Not to Reimburse Cost of Alzheimer's Drug

MT Newswires Live
·
20 Jun

This AI Trader Bought Meta Stock and Dumped Eli Lilly -- Barrons.com

Dow Jones
·
20 Jun

BRIEF-EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment

Reuters
·
20 Jun